Dark

PAVM
PAVmed Inc. Common Stock
stock NASDAQ

At Close

Oct 31, 2025 3:59:30 PM EDT

0.4194USD-0.734%(-0.0031)529,660

0.00Bid 0.00Ask 0.0000Spread

Pre-market

Oct 31, 2025 9:27:30 AM EDT

0.4470USD+5.799%(+0.0245)16,317

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Dec 1, 2021

08:34AM EST Lucid Diagnostics, PAVmed Majority-Owned Subsidiary Highlight Launch Of Its EsoGuard Telemedicine Program In Partnership With Telemedicine Co. UpScriptHealth, No Terms Disclosed Benzinga

Nov 17, 2021

10:12AM EST Mid-Morning Market Update: Markets Down; Lowe's Earnings Beat Estimates Benzinga

Nov 16, 2021

04:15PM EST PAVmed, Lucid Diagnostics See Q3 2021 EsoGuard Related Revenue 200K; Sees GAAP EPS $(0.15) Benzinga

08:31AM EST The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment Benzinga

04:06AM EST Earnings Scheduled For November 16, 2021 Benzinga

Nov 15, 2021

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

Nov 11, 2021

08:39AM EST PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers Benzinga

Oct 18, 2021

05:45PM EDT Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering GlobeNewswire Inc

05:23PM EDT PAVmed 8-K Shows Co. Purchased ~571K Shares In IPO Of Its Majority-Owned Subsidiary, Lucid Diagnostics Benzinga

Oct 14, 2021

08:07AM EDT The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts Benzinga

Oct 13, 2021

10:15PM EDT Lucid Diagnostics Announces Pricing of Initial Public Offering GlobeNewswire Inc

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 7, 2021

11:41AM EDT PAVmed Acquires EsophaCap Manufacturer CapNostics LLC GlobeNewswire Inc

09:33AM EDT PAVmed Acquires EsophaCap Manufacturer CapNostics; Terms Not Disclosed Benzinga

Sep 23, 2021

03:20PM EDT Why PAVmed Shares Are Trading Higher Today Benzinga

09:32AM EDT PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement For Proposed Initial Public Offering Benzinga

Sep 8, 2021

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Aug 12, 2021

04:27PM EDT PAVmed Q2 Adj. EPS $(0.08) Beats $(0.10) Estimate Benzinga

04:26PM EDT CORRECTION: PAVmed Q2 Adjusted EPS $(0.08) Beats $(0.10) Estimate Benzinga

04:25PM EDT PAVmed Q2 EPS $(0.14) Misses $(0.10) Estimate Benzinga

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 10, 2021

09:31AM EDT PAVmed Reports Its Lucid Diagnostics Subsidiary Launches First Lucid Test Centers Benzinga

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Jul 22, 2021

09:31AM EDT PAVmed's Lucid Diagnostics Highlights Launch Of Strategic Partnership With Direct-To-Consumer Telemedicine Co., UpScriptHealth, No Terms Disclosed Benzinga

Jun 24, 2021

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 14, 2021

09:30AM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology industry leader Tim Baxter, to its Board of Directors. Mr. Baxter will serve as Chair of the Companys Nomination Committee and as a member of its Audit Committee. GlobeNewswire Inc

Jun 10, 2021

09:31AM EDT PAVmed Reports Its Lucid Diagnostics Completes European CE Mark Certification Of Its EsoGuard Esophageal DNA Test Benzinga

09:30AM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (Lucid), has completed European IVDD CE Mark certification of its EsoGuard Esophageal DNA Test (EsoGuard). GlobeNewswire Inc

Jun 2, 2021

09:31AM EDT PAVmed Reports Launch Of New Subsidiary, Digital Health Company Veris Health Benzinga

09:30AM EDT New subsidiary Verisacquires privately held oncology digital health company Oncodisc Inc. GlobeNewswire Inc

May 26, 2021

09:31AM EDT PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification For Its EsoCheck Device Benzinga

09:30AM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (Lucid), today announced that Lucids EsoCheck Esophageal Cell Collection Device with Collect+Protect technology (EsoCheck) has received CE Mark certification. GlobeNewswire Inc

May 25, 2021

09:33AM EDT PAVmed Says Receives European CE Mark Certification For CarpX Minimally Invasive Carpal Tunnel Device Benzinga

May 24, 2021

09:30AM EDT PAVmed Says Data Presented At Digestive Disease Week 2021 Support Clinical Utility of Co's Subsidiary Lucid Diagnostics' EsoCheck And EsoGuard Technologies Benzinga

09:30AM EDT Initial NYU experience in 99 patients demonstratedEsoCheck and EsoGuard capable of detectingesophagealprecancerin chronic heartburn patients GlobeNewswire Inc

May 17, 2021

04:03PM EDT PAVmed Q1 EPS $(0.08) Beats $(0.12) Estimate Benzinga

04:00PM EDT PAVmed Provides Business Update and First Quarter 2021 Financial GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 13, 2021

09:30AM EDT Dr. David Poppers to present on his initial experience with Lucids EsoCheck and EsoGuard GlobeNewswire Inc

May 6, 2021

09:30AM EDT Four new senior executives will support growth strategy focused on multi-channel EsoGuardcommercialization GlobeNewswire Inc

May 3, 2021

09:30AM EDT PAVmed to Hold Business Update Conference Call on May 17, 2021 GlobeNewswire Inc

Apr 29, 2021

09:30AM EDT Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid GlobeNewswire Inc

Apr 27, 2021

09:30AM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent UK-based global industry executive, Debbie White, to its Board of Directors. Ms. White will serve on the Companys Audit and Compensation Committees. GlobeNewswire Inc

Apr 15, 2021

09:30AM EDT PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare GlobeNewswire Inc

Apr 8, 2021

09:30AM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmeds Chairman and Chief Executive Officer will present a corporate update at the 20th Annual Needham Healthcare Conference on April 15, 2021 at 8:00 AM EDT. GlobeNewswire Inc

08:14AM EDT The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data Benzinga

Apr 7, 2021

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

Mar 30, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2021 Benzinga

06:23AM EDT Cantor Fitzgerald Initiates Coverage On PAVmed with Overweight Rating, Announces Price Target of $8 Benzinga

Mar 29, 2021

04:52PM EDT PAVmed Shares Move Higher After Hours As Hearing Cantor Initiated Coverage On Stock With Overweight Rating, $8 Price Target Benzinga

Mar 19, 2021

01:19PM EDT PAVmed Form 4 Shows Chairman, CEO Purchased 7,500 Shares Benzinga

Mar 10, 2021

09:30AM EST PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural GlobeNewswire Inc

Mar 3, 2021

09:30AM EST PAVmed Retires Convertible Debt GlobeNewswire Inc

Mar 1, 2021

09:30AM EST PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association (AdvaMed), the worlds leading medical technology trade association, has appointed Lishan Aklog, M.D., PAVmeds Chairman and Chief Executive Officer to its Board of Directors. GlobeNewswire Inc

Feb 23, 2021

09:02AM EST PAVmed Prices 9.8M Share Common Stock Offering For Gross Proceeds Of $45M, Implied Price $4.59/Share Benzinga

09:00AM EST PAVmed Announces Pricing of $45 Million Public Offering of Common GlobeNewswire Inc

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

Feb 22, 2021

04:14PM EST PAVmed Announces Proposed Common Stock Offering, Size Not Disclosed Benzinga

04:13PM EST PAVmed Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

08:20AM EST PAVmed Sees Prelim. Q4 Adj. EPS $(0.12), Had Cash And Equivalents Of $17.3M As Of Dec. 31 Benzinga

08:18AM EST Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company GlobeNewswire Inc

Feb 18, 2021

09:33AM EST PAVmed Says Reschedules Business Update Conference Call On Feb. 22 To 8:30 a.m. EST To Accommodate Schedule Of Subsidiary Lucid Diagnostic Benzinga

09:30AM EST Conference call and live webcast was previously scheduled for 4:30 PM EST GlobeNewswire Inc

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 16, 2021

09:38AM EST PAVmed Announces First US Patient Has Undergone Carpal Tunnel Release Using CarpX Device Benzinga

09:30AM EST PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the first U.S. patient recently underwent successful carpal tunnel release using its CarpX minimally invasive carpal tunnel device. GlobeNewswire Inc

Feb 11, 2021

08:31AM EST Global Cardiovascular Devices Market Now Project to Exceed $71 Billion By 2027 PR Newswire

Feb 9, 2021

09:30AM EST PAVmed to Hold Business Update Conference Call on February 22, 2021 GlobeNewswire Inc

Jan 8, 2021

10:53AM EST PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the Offering) of 6.0 million shares of common stock at a price of $2.24 per share which was priced at-the-market under Nasdaq rules. GlobeNewswire Inc

Jan 6, 2021

09:30AM EST PAVmed Announces Registered Direct Offering Of Common Stock At $2.24/Share Benzinga

09:29AM EST PAVmed Announces Registered Direct Offering of its Common Stock GlobeNewswire Inc

Dec 22, 2020

12:05PM EST PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the Offering) of approximately 5.1 million shares of common stock at a price of $1.60 per share. GlobeNewswire Inc

Dec 18, 2020

09:30AM EST PAVmed Prices 5.1M Share Common Stock Offering At $1.60/Share Benzinga

09:29AM EST PAVmed Announces Pricing of Additional $8.1 Million Common Stock GlobeNewswire Inc

Dec 11, 2020

09:29AM EST PAVmed Prices 5.6M Share Offering At $1.60/Share Benzinga

09:29AM EST PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 5.6 million shares of common stock in a registered direct offering at a price of $1.60 per share for gross proceeds of approximately $8.9 million. GlobeNewswire Inc

Nov 17, 2020

04:00PM EST PAVmed Reports Third Quarter 2020 Financial Results and Provides GlobeNewswire Inc

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

Nov 5, 2020

10:28AM EST Benzinga's Top Upgrades, Downgrades For November 5, 2020 Benzinga

05:50AM EST Ascendiant Capital Initiates Coverage On PAVmed with Buy Rating, Announces Price Target of $5 Benzinga

Nov 2, 2020

09:30AM EST PAVmed to Hold Business Update Conference Call on November 17, 2020 GlobeNewswire Inc

Oct 13, 2020

12:32PM EDT Lake Street Initiates Coverage On PAVmed with Buy Rating, Announces Price Target of $5 Benzinga

Sep 10, 2020

04:33PM EDT PAVmed S-3 Filing Shows Registration For $75M Mixed Securities Offering Benzinga

Sep 8, 2020

09:30AM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced that Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference onTuesday, September 15, 2020 from 8:00 a.m. to 8:30 a.m. Eastern time. GlobeNewswire Inc

Aug 18, 2020

04:15PM EDT PAVmed Reports Second Quarter 2020 Financial Results and Provides GlobeNewswire Inc

04:02AM EDT Earnings Scheduled For August 18, 2020 Benzinga

Aug 14, 2020

07:30AM EDT Exebacase Phase 2 study results published in the Journal of Clinical Investigation GlobeNewswire Inc

Jul 28, 2020

09:30AM EDT PAVmed to Hold Business Update Conference Call on August 18, 2020 GlobeNewswire Inc

Jul 13, 2020

09:30AM EDT PAVmed to Present at Maxim Groups COVID-19 GlobeNewswire Inc